The Gliknik Board of Directors has deep industry expertise with a track record for discovering and developing marketed drugs and generating successful exits for investors.
David S. Block – Chairman and CEO
Dr. Block has served as a member of our Board of Directors since Gliknik was founded. He worked more than 12 years in a series of commercial positions at DuPont Merck and DuPont Pharmaceuticals including sales management, licensing, R&D portfolio planning, market development, and product launch. He was the EVP of International Operations at the time of the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb. From 2002 to 2004, Dr. Block was the Chief Operating Officer of Celera Genomics. Prior to founding Gliknik, he formed and ran a venture-backed CNS start-up. Dr. Block received a BA from Wesleyan University in biopsychology, an M.D. from the University of Pennsylvania School of Medicine where he was class co-president, and an MBA in Entrepreneurism in Health Care from the Wharton School where he was the Beta Gamma Sigma scholar of his class.
David Broser – Non-executive Director
Since 1993, David Broser has been President of RDA Ventures, a family office investment firm that invests as principal or lead investor in a wide variety of industries, where he helps build successful teams. With a diverse skillset spanning several areas, Mr. Broser has skillfully guided RDA’s strategic capital investments in several dozen companies, encompassing hedge funds, private equity, LP investments, real estate, biopharma, theatrical production, and online gaming. His effective leadership has been instrumental in the growth and success of these ventures. Additionally, Mr. Broser holds the position of Managing Partner at Cor Capital Group. David received his JD degree from Boston University and his BBA from the University of Michigan.
Paul A. Friedman, M.D. – Non-executive Director
Dr. Friedman has served as a member of our Board of Directors since 2013. He was the Chairman and CEO of Madrigal Pharmaceuticals, developer of the NASH therapy resmetirom, and was formerly the Chief Executive Officer of Incyte Corporation. Under Dr. Friedman’s leadership, Incyte developed and launched Jakafi® (ruxolitinib), an FDA-approved drug for patients with intermediate or high-risk myelofibrosis. From 1994 to 1998, Dr. Friedman served as President of R & D for the DuPont Merck Pharmaceutical Company and from 1998 to 2001 as the President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of the DuPont Company. From 1991 to 1994, he served as Senior Vice President at Merck Research Laboratories. In these positions, Dr. Friedman has overseen the discovery and development of numerous drugs and brought Sustiva® (efavirenz) to market. Prior to his work at Merck and DuPont, Dr. Friedman was an associate professor of medicine and pharmacology at Harvard Medical School. Dr. Friedman is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He received his A.B. in biology from Princeton University and his M.D. from Harvard Medical School. Dr. Friedman currently serves on the boards of directors of Prelude Therapeutics and Madrigal Pharmaceuticals, Inc. He has previously served on the boards of directors of Incyte Corporation, Durata Therapeutics, Cerulean Pharma Inc., Verastem, Inc., Navitor Pharmaceuticals, and Auxilium Pharmaceuticals.
Richard S. Levy, M.D. – Non-executive Director
Richard S. Levy, M.D. has served as a member of our Board of Directors since 2014. From December 2016 until May 2019 Dr. Levy served as a Senior Advisor of Baker Bros. Advisors LP, a registered investment adviser focused on long-term investments in life-sciences companies. From January 2009 to April 2016, Dr. Levy served as Executive Vice President and Chief Drug Development Officer of Incyte Corporation and prior to that as Senior Vice President of Drug Development beginning in August 2003. Dr. Levy served as Vice President, Biologic Therapies, at Celgene Corporation from 2002 to 2003. From 1997 to 2002, Dr. Levy served in various executive positions with DuPont Pharmaceuticals Company, first as Vice President, Regulatory Affairs and Pharmacovigilance, and thereafter as Vice President, Medical and Commercial Strategy. Dr. Levy served at Sandoz, a predecessor company of Novartis, from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. Dr. Levy also currently serves on the Boards of Madrigal Pharmaceuticals, Kodiak Sciences, Kiniksa Pharmaceuticals and ProTara Therapeutics, all publicly traded biopharmaceutical companies. Prior to joining the pharmaceutical industry, Dr. Levy served as an Assistant Professor of Medicine at the UCLA School of Medicine. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and received his A.B. in Biology from Brown University, his M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.
Charles Polsky, M.D. – Non-executive Director
Charles Polsky, M.D. is a seasoned biotechnology entrepreneur with two decades of experience both as an investor and operator in the life sciences. He received his undergraduate degree in Mathematics at Yale University, and his MD and residency training at the University of Chicago. Dr Polsky worked for several years as a biotech analyst and portfolio manager for William Harris Investors in Chicago before being promoted to CEO of the office. Over the past twenty years he has served in numerous board and advisory capacities for biotech startups, including Tivorsan, Panacos Therapeutics, 3PrimeDx, SonoGene, Rigimmune, Bolden Therapeutics, ReAx and Akava Therapeutics among others. In addition, he remains Board Chair of William Harris Investors and president of WHITCo, a chartered Trust Company in the state of Wyoming.
Dr Polsky focuses his efforts on companies with innovative scientific underpinnings that address large and important areas of unmet clinical need. He is driven by a desire to improve care for patients and their families, focusing on intractable areas of disease that have proven challenging to remedy. In addition to his professional work, Dr Polsky serves on the Investment Committee for the George Shultz Innovation Fund at the University of Chicago. He lives in Chicago with his wife and youngest of four children.
Kyle Rusconi – Non-executive Director
Mr. Rusconi joined the Gliknik Board in 2021. Mr. Rusconi is co-founder of First In Ventures, an entity that works closely with startups and high-net worth networks investing across the biotech, life science, and tech space. Mr. Rusconi began his career as a financial trader on one of the first high-frequency trading desks on Wall Street. While at BNP Paribas and Macquarie, he led and built proprietary trading teams across Asia and North America. He served as country, regional, and global head of high-frequency, quantitative, and fundamental driven strategies over the course of his career while working in Sydney, Tokyo, and New York. He received his BS in Finance from Villanova University.
Raymond F. Schinazi, Ph.D., D.Sc. (Hon.) – Non-executive Director
Dr. Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University and Director of the Scientific Working Group on Viral Eradication for the NIH-sponsored Emory University Center for AIDS Research (CFAR). Dr. Schinazi received his B.Sc. (1972) and Ph.D. (1976) in chemistry from the University of Bath, England. He has authored over 600 peer-reviewed papers and seven books and holds over 100 issued U.S. patents, which have resulted in 26 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV, HBV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine/Emtriva), LdT (telbivudine), and sofosbuvir (Sovaldi), which are now approved by the FDA. He is also the inventor on the use of baricitinib for the treatment of COVID-19 under an FDA Emergency Use Application. He is a founder of five biotechnology companies including Pharmasset Inc. (acquired by Gilead), Triangle Pharmaceuticals (acquired by Gilead), and Idenix Pharmaceuticals (acquired by Merck). More than 90% of HIV-infected individuals in the U.S. on combination therapy take at least one of the drugs he invented with hundreds of thousands of others treated worldwide. His contributions related to HCV cure have already had a profound positive impact on more than 70 million people worldwide suffering from chronic infection. Dr. Schinazi served on the Presidential Commission on AIDS and is the recipient of numerous distinguished awards including the French Légion D’honneur. He served for 35 years for the Department of Veteran Affairs as Senior Research Career Scientist. He currently serves as a Board member for the International Centre for Missing and Exploited Children (ICMEC).